Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07457489 · ClinicalTrials.gov registry record · NA
Vanderbilt Integrated Community TMS for Opioid Recovery
A NA study of Opiod Use Disorder, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT07457489: Recruiting NA study of Opiod Use Disorder, sponsored by Vanderbilt University Medical Center.
NCT07457489 is a NA study of Opiod Use Disorder that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07457489, a NA study of Opiod Use Disorder, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to learn how stimulating a region in the brain influences craving and opioid use. The brain will be stimulated using TMS. Participants may choose to receive brain imaging (magnetic resonance imaging, MRI) as part of this study. The MRI will be used to identify areas in the brain that to stimulate and to measure brain changes as a result of TMS. Participants will be asked to attend a total of 12 visits over about 5 months. Each visit will last between 1-2 hours with breaks. The study will involve interviews, questionnaires, computer tasks, TMS, and optional MRIs. There are minor risks associated with this study. Answering some of the study questionnaires may cause stress or fatigue. The physical risks of TMS are low. Participants may experience mild pain or headache during or after receiving TMS. These symptoms may extend to adjacent areas of the face. The discomfort may be associated with twitching or movement of these areas during stimulation. This is generally transient and can be treated with over-the-counter pain medication. To minimize any risk of hearing loss during TMS, participants wear earplugs for the entire procedure. An evaluation of the participant's medical history will also be completed to ensure that it will be safe for participants to receive TMS. There is no direct benefit to participants from being in this study. However, participation may help others in the future as a result of knowledge gained from the research. The physical risks of the optional MRI are minimal, and a health questionnaire will be filled out before to determine if it is safe for participants to complete the MRI. Confidentiality: All efforts, within reason, will be made to keep personal information in participants' research records confidential but total confidentiality cannot be guaranteed. Documents containing identifiable subject information, like this consent form, will be stored in locked filing cabinets located in the Departments of Ps
Primary Outcome
The primary outcome is to determine the effects of active left-DLPFC targeted iTBS compared to sham on craving in 100 people with OUD. Specifically, this study seeks to provide evidence that L DLFPC-targeted iTBS leads to reduced craving use in individuals with OUD. Participants' craving and drug use will be assessed prior to receiving iTBS, during iTBS intervention and following the end of iTBS (10, 12 and 20 weeks). Craving will be measured using the Visual Analogue Scale (VAS) on the Opioid
Conditions Studied
Interventions
- DEVICE Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Study Locations (2)
Tennessee
- Synaptic Psych - Brentwood
- Vanderbilt University Medical Center Psychiatric Hospital - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2028-01-01 |
| Phase | NA |
What NCT07457489 shows while recruiting
NCT07457489 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Opiod Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Device: Repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.
NCT07457489 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07457489 about?
NCT07457489 is a clinical study titled "Vanderbilt Integrated Community TMS for Opioid Recovery". The main purpose of this study is to learn how stimulating a region in the brain influences craving and opioid use. The brain will be stimulated using TMS. Participants may choose to receive brain imaging (magnetic resonance imaging, MRI) as part of this study. The MRI will be used to identify areas...
What is the current status of trial NCT07457489?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-01-01. Estimated completion is 2028-01-01.
What conditions does trial NCT07457489 study?
This clinical trial studies the following conditions: Opiod Use Disorder.
What interventions are being tested in trial NCT07457489?
The interventions under investigation include: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE).
Who is sponsoring clinical trial NCT07457489?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07457489 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opiod Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07457489's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI